MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
securities in registered...
$6,087,037
Proceeds from sale of
securities in registered...
$4,178,162
Exercise of common stock
warrants
$45,801
Net cash provided by
financing activities
$10,311,000
Net change in cash
$4,067,920
Canceled cashflow
$6,243,080
Stock-based compensation
expense
$1,388,322
Realized loss on digital
assets
$904,394
Accounts payable and
accrued expenses
$380,776
Common stock issued for
services
$171,611
Non-cash lease expense
for right-of-use...
$61,695
Other prepaid
expenses
-$40,828
Net cash used in
investing activities
-$3,172,462
Net cash used in
operating activities
-$3,070,618
Canceled cashflow
$2,947,626
Purchase of digital
assets
$2,637,360
Cash paid for liora
investment
$440,000
Capitalized transaction
costs
$95,102
Net loss
-$6,009,520
Prepaid insurance
$5,784
Research and development
contract liabilities
-$2,940
Back
Back
Cash Flow
source: myfinsight.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)